Stock Events

Stock Events

uniQure N.V. 

$29.17
98
+$0.07+0.24% Wednesday 20:00

Statistics

Day High
29.4
Day Low
27.76
52W High
70.59
52W Low
9.03
Volume
1,738,459
Avg. Volume
-
Mkt Cap
1.82B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-1.49
-1.18
-0.88
-0.57
Expected EPS
-0.838808
Actual EPS
N/A

Financials

-1,236%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
32.2MRevenue
-397.94MNet Income

Analyst Ratings

32.78Average Price Target
The highest estimate is 60.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QURE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap47.64M
Sangamo Therapeutics, Inc. competes in the gene editing and therapy space, focusing on developing genomic medicines for genetic diseases, similar to uniQure's work on gene therapies.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for rare genetic diseases, overlapping with uniQure's target market.
Pfizer
PFE
Mkt Cap146.36B
Pfizer Inc., through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same field as uniQure.
Regenxbio
RGNX
Mkt Cap544.56M
REGENXBIO Inc. is a biotechnology company that develops AAV-based gene therapies for genetic and other diseases, competing in the same space as uniQure.
Sarepta Therapeutics
SRPT
Mkt Cap2.11B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based and gene therapy treatments for rare diseases, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.68B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a next-generation technology that could compete with uniQure's gene therapy approaches.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics AG focuses on the development of gene-based medicines using the CRISPR/Cas9 system, competing in the broader gene therapy and editing market alongside uniQure.

About

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Show more...
CEO
Mr. Christian Klemt
Employees
209
Country
United States
ISIN
NL0010696654

Listings

MX
MX
QUREN.MX
STU
DE
UQ1.STU
XNAS
US
QURE
LSE
GB
0EE0.LSE

0 Comments

Share your thoughts

FAQ

What is uniQure N.V. stock price today?▼
The current price of QURE is $29.17 USD — it has increased by +0.24% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
What is uniQure N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange uniQure N.V. stocks are traded under the ticker QURE.
Is uniQure N.V. stock price growing?▼
QURE stock has risen by +20.79% compared to the previous week, the month change is a +70.68% rise, over the last year uniQure N.V. has showed a +130.59% increase.
What is uniQure N.V. market cap?▼
Today uniQure N.V. has the market capitalization of 1.82B
When is the next uniQure N.V. earnings date?▼
uniQure N.V. is going to release the next earnings report on August 04, 2026.
What were uniQure N.V. earnings last quarter?▼
QURE earnings for the last quarter are -0.85 USD per share, whereas the estimation was -0.86 USD resulting in a +1.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is uniQure N.V. revenue for the last year?▼
uniQure N.V. revenue for the last year amounts to 32.2M USD.
What is uniQure N.V. net income for the last year?▼
QURE net income for the last year is -397.94M USD.
How many employees does uniQure N.V. have?▼
As of May 14, 2026, the company has 209 employees.
In which sector is uniQure N.V. located?▼
uniQure N.V. operates in the Health & Wellness sector.
When did uniQure N.V. complete a stock split?▼
uniQure N.V. has not had any recent stock splits.
Where is uniQure N.V. headquartered?▼
uniQure N.V. is headquartered in Amsterdam, United States.